newsfilter
← Latest News
GlobeNewswire·

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC);